Alcon has acquired privately held Neurotech Pharmaceuticals, providing it ownership of Encelto (revakinagene taroretcel). - The Swiss eye care company paid $550M and may have to pay contingent payments, such as for commercial milestones. - Encelto, an encapsulated cell therapy,...</strong
Alcon has acquired privately held Neurotech Pharmaceuticals, providing it ownership of Encelto (revakinagene taroretcel). – The Swiss eye care company paid $550M and may have to pay contingent payments, such as for commercial milestones. – Encelto, an encapsulated cell therapy,…
proved in 2025, is the
ادخل بحساب جوجل لمشاركة رأيك والتفاعل مع الأخبار — بلا كلمة مرور.
إيميلك يبقى موثّقاً وخصوصيتك محفوظة.
